Since evidence associates both ι and ζ isoforms with pro-invasive biology in NSCLC, atypical PKC inhibition may be a promising therapeutic approach to impair proregression of lung cancer in patients with elevated or activated PKCι and PKCζ. This evidence concerns the gene PRKCI and non-small cell lung carcinoma.